ASH 2020 CLL In-depth

Complete Coverage

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL

A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.

Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL

The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.

Promising Efficacy Seen With LOXO-305 in R/R CLL/SLL

LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.

Real-World Data: Ibrutinib Improves Outcomes vs Chemoimmunotherapy in CLL

Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.

Venetoclax-Rituximab Led to Sustained MRD Negativity in R/R CLL

The combination was also associated with improvements in progression-free and overall survival.

Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD

Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.

Sustained CLL Response Seen With Ibrutinib Plus Venetoclax After MRD Negativity

Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.